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Available online 14 July 2006Abstract—ortho-Chlorodiarylamines in the 2,3,7-trimethylbenzo[b]thiophene series were prepared in high yields (70–85%) by C–N
palladium-catalyzed cross-coupling using P(t-Bu)3 as ligand and NaOt-Bu as base. A palladium-assisted C–C intramolecular cycli-
zation of the coupling products gave thienocarbazoles and the dechlorinated diarylamines. Studies of antimicrobial activity of the
compounds obtained, against representative species of bacteria (Escherichia coli, Pseudomonas aeruginosa, Bacillus cereus and
Bacillus subtilis) and fungi (Candida albicans), were performed. We have also included in the biological assays some pyridine deriv-
atives previously prepared by us, and it was possible to establish some structure–activity relationships (SARs).
 2006 Elsevier Ltd. All rights reserved.1. Introduction
In recent years we have been interested in palladium-
catalyzed C–N cross-couplings in the benzo[b]thio-
phene series.1,2 We reported some general conditions
to obtain diarylamines functionalizing the benzene
ring of the benzo[b]thiophene system with arenes bear-
ing electron-donating or -withdrawing groups. 1b The
antimicrobial activity of diarylamines derivatives of
2,3,5-trimethylbenzo[b]thiophene was already studied
by us.3
For the synthesis of ortho-bromodiarylamines in the
benzo[b]thiophene series we have established diﬀerent
conditions for the functionalization of the benzene or
the thiophene ring. The latter diarylamines were
obtained in moderate to good yields and gave the
corresponding tetracyclic thienocarbazoles and indo-0968-0896/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2006.06.035
Keywords: Benzothiophenes; ortho-Chlorodiarylamines; Palladium;
Thienocarbazoles; Thienocarboline; Antimicrobial activity.
* Corresponding author. Tel.: +351 253604378; fax: +351
253678983; e-mail: mjrpq@quimica.uminho.ptlobenzo[b]thiophenes using a palladium-assisted intra-
molecular cyclization.1c
Bedford and Cazin described the synthesis of ortho-chlo-
rodiphenylamines in high yields by C–N palladium-
catalyzed cross-coupling of halobenzenes with
ortho-chloroanilines using P(t-Bu)3 as ligand and
NaOt-Bu as base.4
In this work, we describe the synthesis of ortho-chloro-
diarylamine derivatives of 2,3,7-trimethylbenzo[b]thio-
phene in high yields, using Bedford’s conditions and
the palladium-assisted C–C intramolecular cyclization
to thienocarbazoles. Using the same type of reactions
we have already reported the synthesis of an ortho-chlo-
rodiheteroarylamine from 3-bromo-2-chloropyridine
and 6-amino-2,3,7-trimethylbenzo[b]thiophene and its
cyclization to the ﬁrst thieno-d-carboline.5 The latter
compound has already shown antiproliferative activity
upon photoactivation, in leukaemia and in solid tumour
cell lines.6
Herein we report studies of the antimicrobial activity of
the compounds prepared including also the pyridine
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lish some structure–activity relationships (SARs).2. Results and discussion
2.1. Synthesis
The ortho-chlorodiarylamines 1a and 1b were prepared
in high yields, by palladium-catalyzed C–N cross-cou-
pling7 of the 6-bromo-2,3,7-trimethylbenzo[b]thiophene8
with ortho-chloroanilines, using Bedford’s conditions4
(Scheme 1).SBr
Cl
NH2
Cl
NH2.HClMeO
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1equiv. 
Scheme 1. Synthesis of ortho-chlorodiarylamines in the 2,3,7-trimethylbenz
P(t-Bu)3 (7 mol%), NaOt-Bu (5 equiv), dry toluene, 105 C, Ar.
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Scheme 2. Intramolecular cyclization to thienocarbazoles 2 and thienocar
(30 mol%), K3PO4 (10 equiv), dry dioxane, 120 C, 20 h, Ar.The diarylamines 1a and 1b were cyclized to the corre-
sponding thienocarbazoles using a palladium-assisted
C–C intramolecular cyclization (Scheme 2) applying
the Maes conditions9 that had been used in the cycliza-
tion of 3-chloro-2-(4-piridinylamino)pyridine, needing
in our case a bigger amount of Pd(OAc)2. This reaction
can be seen as an intramolecular C–H activation by a
Pd(II) complex, resulting of oxidative addition of com-
pounds 1 to Pd(0), presumably by an electrophilic
displacement mechanism, to give a six-membered palla-
cycle which subsequently yields the thienocarbazoles 2
by reductive elimination, as suggested for the synthesis
of carbazoles from ortho-chlorodiphenylamines.4N S
Cl
H
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diarylamines 3a and 3b were obtained as major products
and the starting ortho-chlorodiarylamines were also
isolated. In the cyclization of 1b, two thienocarbazoles
2b and 2c were formed (Scheme 2). The latter can be
the result of the electrophilic attack of Pd(OAc)2 on
the aromatic rings of 3b with extrusion of Pd(0).1a
As already reported by us the cyclization of the ortho-
chlorodiarylamine 1c gave the thienocarboline 4 in high
yield by the same method (Scheme 2).5
2.2. In vitro antimicrobial activity evaluation
An evaluation of the antibacterial activity using two
Gram-negative (Escherichia coli and Pseudomonas
aeruginosa) and two Gram-positive bacteria (Bacillus
subtilis and Bacillus cereus) and the antifungal activity
using Candida albicans as a representative species of fun-
gi was assessed for compounds 1a–c, 2a,b, 3b and 4. The
minimal inhibitory concentration (MIC in lg/mL) was
determined using an adaptation of agar streak dilution
method based on radial diﬀusion.10,11 In the same condi-
tions diﬀerent concentrated solutions of ampicillin (anti-
bacterial) and cycloheximide (antifungal) were used as
standards. The MIC was considered to be the lowest
concentration of the tested compound which inhibits
growth of bacteria or fungi on the plate. The diameters
of the inhibition zones corresponding to the MICs are
presented in Table 1. The compounds tested are not
active against Pseudomonas aeruginosa starting from
DMSO solutions of 1000 lg/mL of each compound.
From the analysis of Table 1 it is possible to establish
some SARs. The only active compound against E. coli
in the concentrations tested is the ortho-chlorodiaryl-
amine 1b (MIC 12.5 lg/mL), the methoxy group being
the responsible for the activity. Against Gram + bacteria
the MICs for 1b are much lower than those for 1a. Com-
paring 1bwith 1c (the pyridine derivative) the latter shows
to be more active against B. cereus (MIC 3.13 lg/mL) but
less active againstB. subtilis. AgainstC. albicans 1b and 1c
present the sameMIC (25 lg/mL) which is lower than the
MIC obtained for 1a (50 lg/mL).
Comparing 1b with the corresponding dechlorinated
diarylamine 3b, the MICs for the latter are much moreTable 1. Antimicrobial activity of compounds 1a–c, 2a,b, 3b and 4
Compounds MIC in
E. coli CECT 101 B.
CE
1a Not activea 25
1b 12.5 (6) 6.2
1c Not activea 3.1
3b Not activea 0.0
2a Not activea 25
2b Not activea 0.5
4 Not activea 6.2
Ampicillin 6.25 (15) 3.1
Cycloheximide — —
CECT-Spanish type culture collection of Valencia University.
a Not active starting from 1000 lg/mL.lower for B. cereus and for C. albicans (0.05 lg/mL)
and even lower than those for ampicillin and
cycloheximide.
Among the cyclized products 2a and 2b, the methoxylat-
ed thienocarbazole 2b presents the lower MICs. The thi-
eno-d-carboline 4 presents better results than the
corresponding thienocarbazole 2a for B. cereus and
C. albicans and the same MIC for B. subtilis which is
lower than the MIC for ampicillin.3. Conclusion
ortho-Chlorodiarylamines in the 2,3,7-trimethylben-
zo[b]thiophene series were prepared in high yields
by palladium-catalyzed C–N cross-coupling. A palla-
dium-assisted C–C intramolecular cyclization gave the
corresponding thienocarbazoles in low to moderate
yields, and the dechlorinated diarylamines as major
products. Studies of antimicrobial activity were per-
formed using the synthesized compounds and including
a thieno-d-carboline and its ortho-chlorodiarylamine
precursor, previously prepared by us. Some structure–
activity relationships were established and the impor-
tance of the methoxylated compounds is pointed out
(very low MICs). The thienocarboline showed lower
MICs for B. cereus and for C. albicans than the corre-
sponding thienocarbazole but for B. subtilis both pres-
ent the same MIC.4. Experimental
4.1. Materials and methods
Melting points were determined on a Gallenkamp appa-
ratus and are uncorrected. The 1H NMR spectra were
measured on a Varian Unity Plus at 300 MHz.
Spin–spin decoupling was used to assign the signals.
The 13C NMR spectra were measured in the same
instrument at 75.4 MHz (using DEPT h 45).
Elemental analyses were determined on a LECO CHNS
932 elemental analyser. Mass spectra (EI) and HRMS
were made by the mass spectrometry service of Univer-
sity of Vigo-Spain.lg/mL (zone of inhibition in mm)
cereus
CT148
B. subtilis
CECT498
C. albicans
CECT 1394
(8) 50 (6) 50 (11)
5 (8) 6.25 (5) 25 (5)
3 (7) 25 (7) 25 (8)
5 (9) 6.25 (12) 0.05 (9)
(15) 3.13 (8) 100 (10)
(9) 0.05 (13) 0.05 (10)
5 (15) 3.13 (10) 25 (8)
3 (13) 12.5 (10) —
— 12.5 (5)
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Nagel silica gel 230–400 mesh. Petroleum ether refers to
the boiling range 40–60 C. Ether refers to diethyl ether.
When solvent gradient was used, the increase of polarity
was done gradually from neat petroleum ether to mix-
tures of ether/petroleum ether increasing 10% of ether
until the isolation of the product. Preparative layer
chromatography (PLC) was performed in 20 · 20 cm2
plates Macherey–Nagel silica plates layer 2 mm SIL
G-200 UV254. P(t-Bu)3 was purchased from Strem as
an hexane solution.
For the in vitro antimicrobial activity, suspensions of
the microorganism were prepared to contain approxi-
mately 108 cfu/mL and the plates were inoculated.
A stock solution of the synthesized compound
(1000 lg/mL) in DMSO was prepared and graded dilu-
tions of the tested compounds were incorporated in a
cavity (depth 3 mm, diameter 4 mm) made in the center
of the petridish (nutrient agar for antibacterial activity
and Sabouraud vs dextrose agar medium for antifungal
activity). The plates were incubated at 37 C (for
bacteria) and at 30 C (for fungi) for 24 h in duplicate.
Positive control using only inoculation and nega-
tive control using only DMSO in the cavity were carried
out.
4.2. General procedure for the synthesis of ortho-chloro-
diarylamines 1a and 1b
In a dry Schlenk tube it was poured under Ar with
stirring, dry toluene (3–5 mL) 6-bromo-2,3,7-trim-
ethylbenzo[b]thiophene, Pd(OAc)2 (5 mol %), P(t-Bu)3
(7 mol %), NaOt-Bu (5 equiv) and the amine (2-chloro-
aniline or 2-chloro-m-anisidine hydrochloride). The
mixture was heated under Ar for some hours at 105 C
(following by TLC). After cooling, water and ether were
added and the phases were separated. The organic phase
was dried (MgSO4), ﬁltered and removal of the solvent
under reduced pressure gave an oil (residues of toluene
were removed with methanol) which was submitted to
column chromatography using 10% ether/petroleum
ether as eluent, to give the ortho-chlorodiarylamines.
4.2.1. 6-(2-Chlorophenyl)amino-2,3,7-trimethylbenzo [b]thi-
ophene (1a). From 6-bromo-2,3,7-benzo[b]thiophene
(150 mg, 0.590 mmol) and 2-chloroaniline (81.0 mg,
0.640 mmol) and heating for 5 h compound 1a was ob-
tained as a colourless solid (152 mg, 85%). Crystallization
from ether/petroleum ether gave colourless crystals, mp
124–126 C. 1H NMR (CDCl3): 2.31 (3H, s, CH3), 2.41
(3H, s, CH3), 2.51 (3H, s, CH3), 5.97 (1H, s, N–H), 6.63
(1H, dd, J = 8.1 and 1.5 Hz, H-60), 6.72 (1H, td, J = 8.1
and 1.5 Hz, H-40), 7.03 (1H, td, J = 8.1 and 1.5 Hz, H-
50), 7.27 (1H, d J = 8.4 Hz, ArH), 7.35 (1H, dd, J = 8.1
and 1.5 Hz, H-30), 7.45 (1H, d, J = 8.4 Hz, ArH) ppm.
13C NMR (CDCl3): 11.48 (CH3), 13.86 (CH3), 15.96
(CH3), 113.70 (CH), 118.69 (CH), 119.38 (CH), 119.59
(C), 122.57 (CH), 126.80 (C), 127.48 (CH), 127.73 (C),
129.34 (CH), 133.27 (C), 134.24 (C), 138.42 (C), 139.75
(C), 142.58 (C) ppm. Anal. Calcd for C17H16ClNS: C,
67.65; H, 5.34; N, 4.64; S, 10.62. Found: C, 67.46; H,
5.52; N, 4.78; S, 10.63.4.2.2. 6-(2-Chloro-5-methoxyphenyl)amino-2,3,7-trim-
ethylbenzo[b]thiophene (1b). From 6-bromo-2,3,
7-benzo[b]thiophene (150 mg, 0.590 mmol) and 2-chlo-
ro-m-anisidine hydrochloride (115 mg, 0.590 mmol)
and heating for 2 h, compound 1b was isolated as a col-
ourless solid (135 mg, 70%). Crystallization from ether/
petroleum ether gave colourless crystals, mp 152–
154 C. 1H NMR (CDCl3): 2.32 (3H, s, ArCH3), 2.42
(3H, s, ArCH3), 2.52 (3H, s, ArCH3), 3.65 (3H, s,
OCH3), 5.95 (1H, br s, N–H), 6.20 (1H, d, J = 3 Hz,
H-6 0), 6.29 (1H, dd, J = 8.7 and 3 Hz, H-4 0), 7.24 (1H,
d, J = 8.7 Hz, H-3 0), 7.28 (1H, d, J = 8.4 Hz, ArH),
7.45 (1H, d, J = 8.4 Hz, ArH) ppm. 13C NMR: 11.45
(CH3), 13.84 (CH3), 15.95 (CH3), 55.32 (OCH3), 99.77
(CH), 103.97 (CH), 111.58 (C), 119.42 (CH), 122.75
(CH), 126.95 (C), 127.73 (C), 129.59 (CH), 133.35 (C),
134.03 (C), 138.55 (C), 139.78 (C), 143.45 (C), 159.35
(C) ppm. MS m/z (%): 334 (8), 333 (M+ 37Cl, 38), 332
(22) 331 (M+ 35Cl, 100). Anal. Calcd for C18H18ClNOS:
C, 65.15; H, 5.47; N, 4.22; S, 9.66. Found: C, 64.97; H,
5.58; N, 4.33; S, 9.65.
4.3. General procedure for the synthesis of thieno-
carbazoles 2
In a dry Schlenk tube it was poured under Ar with stir-
ring, dry dioxane (6–8 mL), Pd(OAc)2 (40 mol %),
P(t-Bu)3 (30 mol %), the ortho-chlorodiarylamine 1a or
1b and ﬁnely ground K3PO4 (10 equiv). The mixture
was heated under Ar for 20 h at 120 C. After cooling
ethyl acetate was added and the mixture was ﬁltered.
Removal of solvents gave an oil which was submitted
to PLC (several elutions) to give thienocarbazoles 2
and the diarylamines 3. The starting materials were also
isolated as the less polar products.
4.3.1. 2,3,10-Trimethyl-9H-thieno[2,3-b]carbazole (2a) and
6-(phenyl)amino-2,3,7-trimethylbenzo[b]thiophene (3a).
From compound 1a (70.0 mg, 0.233 mmol) and PLC
(25% ether/petroleum ether), diarylamine 3a was isolated
as a white solid (25.0 mg, 40%), mp 133–135 C. 1H
NMR (CDCl3): 2.29 (3H, s, CH3), 2.41 (3H, s, CH3),
2.49 (3H, s, CH3), 5.48 (1H, s, NH), 6.79–6.86 (3H,
m, ArH), 7.18–7.29 (3H, m, ArH), 7.41 (1H, d,
J = 8.4 Hz, ArH). 13C NMR (CDCl3): 11.45 (CH3),
13.80 (CH3), 15.97 (CH3), 115.41 (2 · CH), 119.21
(CH), 119.24 (CH), 120.51 (CH), 124.50 (C), 127.69
(C), 129.23 (2 · CH), 132.34 (C), 135.80 (C), 137.34
(C), 139.90 (C), 145.78 (C) ppm. Anal. Calcd for
C17H17NS: C, 76.36; H, 6.41; N, 5.24; S, 11.99. Found:
C, 76.56; H, 6.23; N, 4.89; S, 11.72. Thienocarbazole 2a
was obtained as a white solid (18.5 mg, 30%), mp 210–
211 C. 1H NMR (CDCl3): 2.42 (3H, s, CH3), 2.54 (3H,
s, CH3), 2.70 (3H, s, CH3), 7.23–7.29 (1H, m, Ar–H),
7.40–7.46 (2H, m, Ar–H), 7.86 (1H, s, NH), 8.11–8.16
(2H, m, Ar–H) ppm. 13C NMR (CDCl3): 11.80 (CH3),
14.01 (CH3), 15.17 (CH3), 109.69 (CH), 110.51 (CH),
111.59 (C), 119.23 (CH), 120.24 (CH), 122.24 (C),
124.20 (C), 125.70 (CH), 127.46 (C), 130.19 (C),
135.16 (C), 136.61 (C), 136.87 (C), 140.33 (C) ppm.
MS m/z (%): 267 (M++2, 6), 266 (M++1, 20), 265
(M+, 100), 250 (19); calcd for C17H15NS: 265.0925.
Found M+: 265.0917.
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zole (2b), 5-methoxy-2,3,10-trimethyl-9H-thieno[2,3-b] car-
bazole (2c) and 6-(3-methoxyphenyl)amino-2,3,
7-trimethylbenzo[b]thiophene (3b). From compound 1b
(50.0 mg, 0.151 mmol) and PLC (35% ether/petroleum
ether), diarylamine 3b was isolated as a white solid
(18.0 mg, 40%), mp 103–105 C. 1H NMR (CDCl3):
2.30 (3H, s, Ar–CH3), 2.41 (3H, s, Ar–CH3), 2.50 (3H,
s, Ar–CH3), 3.75 (3H, s, OCH3), 5.48 (1H, br s, NH),
6.34–6.42 (3H, m, ArH), 7.12 (1H, t, J = 8 Hz, H-50),
7.28 (1H, d, J = 8.4 Hz, ArH), 7.41 (1H, d, J = 8.4 Hz,
ArH). 13C NMR (CDCl3): 11.44 (CH3), 13.80 (CH3),
15.97 (CH3), 55.12 (OCH3), 101.06 (CH), 104.44 (CH),
108.10 (CH), 119.22 (CH), 121.07 (CH), 124.96 (C),
127.69 (C) 129.98 (CH), 132.51 (C), 135.51 (C), 137.55
(C), 139.80 (C), 147.35 (C), 160.77 (C). MS m/z (%):
299 (M++2, 7), 298 (M++1, 21), 297 (M+, 100). Anal.
Calcd for C18H19NOS: C, 72.69; H, 6.44; N, 4.71; S,
10.78. Found: C, 72.49; H, 6.38; N, 4.89; S, 10.54.
Thienocarbazole 2c was isolated as a white solid
(4.50 mg, 10%), mp 214–216 C. 1H NMR (CDCl3):
2.44 (3H, s, ArCH3), 2.54 (3H, s, ArCH3), 2.69 (3H, s,
ArCH3), 4.15 (3H, s, OCH3), 6.72 (1H, d, J = 7.9 Hz,
ArH), 7.07 (1H, d, J = 7.9 Hz, ArH), 7.36 (1H, t,
J = 7.9 Hz, H-7), 7.89 (1H, s, NH), 8.35 (1H, s, H-4).
MS m/z (%): 297 (M++2, 10), 296 (M++1, 16), 295
(M+, 70). HRMS C18H17NOS: calcd M
+ 295.1031;
found 295.1034.
Thienocarbazole 2b was isolated as the most polar
product, as a white solid (13.5 mg, 30%), mp 190–
192 C. 1H NMR (CDCl3): 2.41 (3H, s, ArCH3), 2.53
(3H, s, ArCH3), 2.66 (3H, s, ArCH3), 3.93 (3H, s,
OCH3), 6.86 (1H, dd, J = 8.6 and 2.1 Hz, H-6), 6.96
(1H, d, J = 2.1 Hz, H-8), 7.79 (1H, br s, NH), 7.98–
8.01 (2H, d overlapped with a s, H-4 and H-5). 13C
NMR (CDCl3): 11.82 (CH3), 14.01 (CH3), 15.14
(CH3), 55.63 (OCH3), 95.03 (CH), 107.53 (CH),
108.91 (CH), 111.42 (C), 114.48 (C), 118.04 (C),
120.95 (CH), 122.42 (C), 127.46 (C), 130.10 (C),
135.22 (C), 136.70 (C), 141.65 (C), 159.00 (C). MS
m/z (%): 297 (M++2, 7), 296 (M++1, 22), 295 (M+,
100). HRMS C18H17NOS: calcd M
+ 295.1031; found
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